In-depth analysis of key pipeline products for head and neck cancer in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK), including new clinical data and a comparative evaluation of clinical and commercial drug attributes to determine competitiveness in the marketplace.
Gilotrif has had a troubled development thus far and is not expected to gain regulatory approval in the US, Japan, or five major EU markets. However, the drug experiences limited off-label use due to its category 2B recommendation from the National Comprehensive Cancer Network, and is under Phase III development for use in emerging markets.
Imfinzi is expected to be the third immunotherapy approved for the treatment of head and neck cancer, and will face significant competition from established immunotherapies. In particular, Opdivo and Imfinzi are both under late-phase development for first-line use in combination with CTLA-4 inhibitors Yervoy and tremelimumab, respectively. Nonetheless, Imfinzi is still likely to experience modest uptake due to the lack of treatment options currently approved for head and neck cancer.
Merck KGaA and Pfizer will attempt to minimize direct competition with other immunotherapies by positioning Bavencio for first-line and maintenance use in combination with chemoradiotherapy in locally advanced patients. While maintenance therapy in advanced head and neck cancer is not well established, the lack of competition could allow the drug to gain modest uptake.
Key Topics Covered:
- Executive Summary
- Clinical Pipeline Overview
- Recently Discontinued Drugs
- Comparator Therapy
- Product profile (late stage): Gilotrif
- Product profile (late stage): Javlor
- Product profile (late stage): Keytruda
- Product profile (late stage): Multikine
- Product profile (late stage): Opdivo
- Product profile (late stage): Reolysin
Product profile (late stage): durvalumab
For more information about this report visit https://www.researchandmarkets.com/research/8wrtql/head_and_neck?w=4